We tested whether genome rearrangement is a prerequisite step for the creation of fusion transcripts from fusion-susceptible pairs by choosing EML4-ALK fusion transcripts for this test because EML4-ALK is a fusion-susceptible pair (Fig. 6A), EML4-ALK fusion transcripts are detected in one of our new tumor samples (sample no. 44) (Fig. 6B), and there is an FDA-approved diagnosis kit (Vysis ALK Break Apart FISH) based on DNA FISH detection of the EML4-ALK fusion gene. Here, EML4 is linked to neoplasm.